Results 161 to 170 of about 22,494 (197)
Deactylase inhibition in myeloproliferative neoplasms [PDF]
, 2010 Sridurga Mithraprabhu +3 more
core +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Reactions Weekly, 2003
Imatinib mesylate (imatinib) is an orally administered competitive inhibitor of the tyrosine kinases associated with the KIT protein (stem cell factor receptor), ABL protein and platelet-derived growth factor receptors. The KIT tyrosine kinase is abnormally expressed in gastrointestinal stromal tumour (GIST), a rare neoplasm for which there has been no
Monique P Curran +2 more
+22 more sources
Imatinib mesylate (imatinib) is an orally administered competitive inhibitor of the tyrosine kinases associated with the KIT protein (stem cell factor receptor), ABL protein and platelet-derived growth factor receptors. The KIT tyrosine kinase is abnormally expressed in gastrointestinal stromal tumour (GIST), a rare neoplasm for which there has been no
Monique P Curran +2 more
+22 more sources
Clinical Journal of Oncology Nursing, 2002
Imatinib is an example of a new group of drugs being developed using the principle of molecular targeting. Imatinib is able to kill the cancer cells and not the body's healthy cells. Imatinib mesylate is indicated for the treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors and ...
Kathy Wilkinson, Monica P. Davey
+12 more sources
Imatinib is an example of a new group of drugs being developed using the principle of molecular targeting. Imatinib is able to kill the cancer cells and not the body's healthy cells. Imatinib mesylate is indicated for the treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors and ...
Kathy Wilkinson, Monica P. Davey
+12 more sources
Another Look at Imatinib Mesylate
New England Journal of Medicine, 2006Imatinib mesylate may affect particular signaling pathways that increase susceptibility to congestive heart failure.
Strebhardt, K., Ullrich, A.
openaire +5 more sources
2014
Imatinib (INN), marketed by Novartis as Gleevec (United States) or Glivec (Europe/Australia/Latin America), received Food & Drug Administration (FDA) approval in May 2001 and is a tyrosine kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.
Badraddin M H, Al-Hadiya +2 more
openaire +2 more sources
Imatinib (INN), marketed by Novartis as Gleevec (United States) or Glivec (Europe/Australia/Latin America), received Food & Drug Administration (FDA) approval in May 2001 and is a tyrosine kinase inhibitor used in the treatment of multiple cancers, most notably Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia.
Badraddin M H, Al-Hadiya +2 more
openaire +2 more sources
2009
Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents, so-called small molecules. They have a high selectivity against a specific molecular target known to be the cause for the establishment and maintenance of the malignant phenotype ...
openaire +6 more sources
Imatinib mesylate (Gleevec, Glivec [Novartis, Basel, Switzerland], formerly referred to as STI571 or CGP57148B) represents the paradigm of a new class of anticancer agents, so-called small molecules. They have a high selectivity against a specific molecular target known to be the cause for the establishment and maintenance of the malignant phenotype ...
openaire +6 more sources
Imatinib mesylate-induced acute hepatotoxicity
Journal of Oncology Pharmacy Practice, 2023Introduction Imatinib is a first-line selective tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia. Although imatinib-induced hepatotoxicity may aggravate the patient's clinical condition and alter the treatment plan, the mechanism of imatinib-induced hepatotoxicity has rarely been investigated. Case report We report a 51-year-
Imen Frikha +5 more
openaire +2 more sources
Imatinib Mesylate (Gleevec) Hepatotoxicity
Digestive Diseases and Sciences, 2007Imatinib mesylate (Gleevec; Novartis Pharmaceuticals Corporation, East Hanover, NJ), formerly known as STI571, is a specific inhibitor of BCR-ABL tyrosine kinase. It is widely used for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) and c-kit (CD117) positive unresectable and/or metastatic malignant ...
Ayse L, Mindikoglu +5 more
openaire +2 more sources